Growth defects resulting from inhibiting ERG20 and RAM2 in Candida glabrata

FEMS Microbiology Letters

Volumn 317, Issue 1, 2011, Pages 27-33

  Nakayama, Hironobu ^a   Ueno, Keigo ^b,c   Uno, Jun ^b   Nagi, Minoru ^c,d   Tanabe, Koichi ^c   Aoyama, Toshihiro ^e   Chibana, Hiroji ^b   Bard, Martin ^f  

^a SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^e SUZUKA NATIONAL COLLEGE OF TECHNOLOGY   (Japan)

^f INDIANA UNIVERSITY   (United States)

Author keywords

Antifungal target; Candida glabrata; Farnesyl pyrophosphate synthase; Isoprenoid; Prenyltransferase

Indexed keywords

DIMETHYLALLYLTRANSFERASE; GERANYLTRANSFERASE; PROTEIN ERG20; PROTEIN RAM2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; CONTROLLED STUDY; ERG20 GENE; FUNGAL GENE; FUNGAL STRAIN; FUNGUS GROWTH; FUNGUS MUTANT; GENE EXPRESSION; GENE REPRESSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PRENYLATION; RAM2 GENE;

ANIMALS; CANDIDA GLABRATA; CANDIDIASIS; DIMETHYLALLYLTRANSTRANSFERASE; DISEASE MODELS, ANIMAL; FUNGAL PROTEINS; GERANYLTRANSTRANSFERASE; MICE; PROTEIN PROCESSING, POST-TRANSLATIONAL; VIRULENCE;

CANDIDA GLABRATA; EUKARYOTA;

EID: 79952180958     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/j.1574-6968.2010.02205.x     Document Type: Article

References (27)

1. Andres DA, Goldstein JL, Ho YK & Brown MS (1993) Mutational analysis of α-subunit of protein farnesyltransferase. Evidence for a catalytic role. J Biol Chem 268: 1383-1390.
2. Bard M, Sturm AM, Pierson CA et al. (2005) Sterol uptake in Candida glabrata: rescue of sterol auxotrophic strains. Diagn Micr Infec Dis 52: 285-293.
3. Barns SM, Lane DJ, Sogin ML, Bibeau C & Weisburg WG (1991) Evolutionary relationships among pathogenic Candida species and relatives. J Bacteriol 173: 2250-2255.
4. Fidel PL Jr, Vazquez JA & Sobel JD (1999) Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 12: 80-96.
5. Gelb MH, Brunsveld L, Hrycyna CA et al. (2006) Therapeutic intervention based on protein prenylation and associated modifications. Nat Chem Biol 2: 518-528.
6. Ito H, Fukuda Y, Murata K & Kimura A (1983) Transformation of intact yeast cells treated with alkali cations. J Bacteriol 153: 163-168.
7. Jiang Y, Rossi G & Ferro-Novick S (1993) Bet2p and Mad2p are components of a prenyltransferase that adds geranylgeranyl onto Ypt1p and Sec4p. Nature 366: 84-86.
8. Kelly R, Card D, Register E et al. (2000) Geranylgeranyltransferase I of Candida albicans: null mutants or enzyme inhibitors produce unexpected phenotypes. J Bacteriol 182: 704-713.
9. Kitada K, Yamaguchi E & Arisawa M (1995) Cloning of the Candida glabrata TRP1 and HIS3 genes, and construction of their disruptant strains by sequential integrative transformation. Gene 165: 203-206.
10. Kuranda K, François J & Palamarczyk G (2010) The isoprenoid pathway and transcriptional response to its inhibitors in the yeast Saccharomyces cerevisiae. FEMS Yeast Res 10: 14-27.
11. Lorenz RT & Parks LW (1990) Effects of lovastatin (mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae. Antimicrob Agents Ch 34: 1660-1665.
12. Macreadie IG, Johnson G, Schlosser T & Macreadie PI (2006) Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett 262: 9-13.
13. Mayer ML, Caplin BE & Marshall MS (1992) CDC43 and RAM2 encode the polypeptide subunits of a yeast type I protein geranylgeranyltransferase. J Biol Chem 267: 20589-20593.
14. Mazur P, Register E & Bonfiglio CA (1999) Purification of geranylgeranyl-transferase I from Candida albicans and cloning of the CaRAM2 and CaCDC43 genes encoding its subunits. Microbiology 145: 1123-1135.
15. Nagi M, Tanabe K, Takano Y et al. (2009) Serum or bile affects the in vitro azole susceptibilities of Candida spp. Jpn J Infect Dis 62: 306-308.
16. Nagi M, Nakayama H, Tanabe K et al. Transcription factors CgUPC2A and CgUPC2B regulate ergosterol biosynthetic gene in Candida glabrata. Genes Cells 16: 80-89.
17. Nakayama H & Arisawa M (2003) Evaluation of targets for antifungal drugs using a system to regulate gene expression. Nippon Ishinkin Gakkai Zasshi 44: 107-114.
18. Nakayama H, Izuta M, Nagahashi S et al. (1998) A controllable gene-expression system for the pathogenic fungus Candida glabrata. Microbiology 144: 2407-2415.
19. Nakayama H, Izuta M, Nakayama N, Arisawa M & Aoki Y (2000) Depletion of the squalene synthase (ERG9) gene does not impair growth of Candida glabrata in mice. Antimicrob Agents Ch 44: 2411-2418.
20. Oldfield E (2010) Targeting isoprenoid biosynthesis for drug discovery: bench to bedside. Accounts Chem Res 43: 1216-1226.
21. Omer CA & Gibbs JB (1994) Protein prenylation in eukaryotic microorganisms: genetics, biology and biochemistry. Mol Microbiol 11: 219-225.
22. Pfaller MA & Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-163.
23. Schafer WR, Kim R, Sterne R et al. (1989) Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 245: 379-385.
24. Song JL & White TC (2003) RAM2: an essential gene in the prenylation pathway of Candida albicans. Microbiology 149: 249-259.
25. Westermeyer C & Macreadie IG (2007) Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata. FEMS Yeast Res 7: 436-441.
26. Wikhe K, Westermeyer C & Macreadie IG (2007) Biological consequence of statin in Candida species and possible implications for human health. Biochem Soc T 35: 1529-1532.
27. Xiong Q, Hassan SA, Wilson WK et al. (2005) Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors. Antimicrob Agents Ch 49: 518-524.